• AMG 487 CXCR3 Antagonist Workflow

  2026-08-24

  AMG 487 provides a practical way to separate CXCR3-dependent chemokine signaling from state-specific macrophage biology. This workflow connects migration, calcium flux, autophagy, polarization, and inflammatory lung-injury models while highlighting controls that prevent misleading potency shifts.

• mRNA Lipid Nanoparticle Formulation and Evaluation

  2026-08-23

  Ma, VanKeulen-Miller, and Fenton present an integrated workflow that connects mRNA lipid nanoparticle formulation with physicochemical characterization, cellular testing, mechanistic analysis, and in vivo evaluation. Its main practical contribution is a structured, adaptable protocol that helps researchers identify whether performance is limited by particle quality, cellular uptake, endosomal escape, expression, biodistribution, or tolerability.

• Deuterium-Labeled Degarelix Acetate Synthesis

  2026-08-22

  The reference study reports an efficient 13-step route to deuterium-labeled degarelix acetate, using D2O/D3PO4-mediated isotope exchange to prepare a d7-naphthyl amino-acid building block. The resulting labeled material was designed as an internal standard for absorption, distribution, metabolism, and excretion studies, offering a practical analytical resource for translational prostate cancer research.

• Ferrostatins Block Lipid Damage Across Disease Models

  2026-08-21

  Skouta and colleagues established ferrostatin-1 as a selective inhibitor of ferroptosis that protects cells by suppressing oxidative lipid damage rather than by broadly eliminating reactive oxygen species. By testing disease-relevant models and developing ferrostatin analogues, the study connected lipid peroxidation with phenotypes in neurodegeneration, developmental brain injury, and kidney dysfunction.

• ATRX-Deficient Glioma: RTK and PDGFR Inhibitor Sensitivity

  2026-08-21

  The reference study identifies ATRX loss as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data further support evaluating ATRX status when interpreting RTK inhibitor and temozolomide treatment responses, while underscoring the need for clinical validation.

• AMG 487: CXCR3 Antagonist Workflows

  2026-08-20

  AMG 487 enables state-aware CXCR3 antagonist experiments spanning calcium signaling, chemokine-directed migration, macrophage polarization, and inflammatory injury models. Its key advantage is mechanistic resolution: researchers can compare proximal receptor blockade with downstream LAMP1-linked phenotype changes rather than treating all inflammatory responses as equivalent.

• AMG 487: A Practical CXCR3 Antagonist Workflow

  2026-08-20

  AMG 487 enables receptor-level interrogation of CXCR3 signaling across migration, calcium flux, and macrophage-polarization assays. This workflow emphasizes state-matched controls, orthogonal readouts, and troubleshooting for inflammation and acute lung injury research.

• BAY-826: Causal Mapping of Retinal Survival

  2026-08-19

  BAY-826 is a potent small molecule inhibitor for testing angiopoietin-linked retinal signaling. This article focuses on causal assay design, pharmacological interpretation, and how to distinguish Müller cell-mediated neuroprotection from direct neuronal effects.

• AMG 487 for CXCR3 Signaling Workflows

  2026-08-19

  AMG 487 provides a practical pharmacological handle for separating CXCR3-dependent chemokine signaling from downstream macrophage, migration, and calcium responses. This workflow-focused guide shows how to use the compound to test state-dependent CXCL10-CXCR3 biology while controlling solubility, timing, and interpretation limits.

• o-Agatoxin IVA and Cortical Excitotoxicity

  2026-08-18

  Lustig, Ahern, and Greenberg tested whether blocking P- and Q-type calcium channels with o-Agatoxin IVA could protect cortical neurons from excitotoxic injury triggered by veratridine, ouabain, or NMDA. The study found no neuroprotection despite the toxin’s ability to inhibit depolarization-evoked glutamate release, showing that suppressing presynaptic release is not necessarily sufficient to prevent downstream neuronal death.

• NSP2–MYB40 Links Flavonoids to Root Symbiosis

  2026-08-18

  Gao et al. identify an NSP2–MYB40 transcriptional module that connects flavonoid biosynthesis with rhizobial nodulation and arbuscular mycorrhizal colonization in Medicago truncatula. The study combines regulatory, biochemical, genetic, and symbiotic evidence to show how nutrient-responsive metabolism can tune nitrogen acquisition under changing microbial conditions.

• Kinase Control of ECM Uptake in Cancer Migration

  2026-08-17

  Martinez and colleagues developed a live-cell, high-content assay that reveals how extracellular matrix internalisation contributes to invasive carcinoma cell migration. Their findings identify an α2β1 integrin–MAP3K1–p38β axis, involving PPP2R1A and NHE1, as a mechanistic regulator of ECM trafficking and a potential vulnerability in invasive and treatment-resistant tumours.

• 3-Methyladenine in Autophagy Research

  2026-08-16

  3-Methyladenine, or 3-MA, helps researchers test whether autophagy contributes to stress responses, neuronal injury, tumor-cell survival, or migration phenotypes. This guide combines mechanism-aware dosing, flux-conscious readouts, and troubleshooting strategies for more defensible PI3K-pathway experiments.

• Indomethacin Workflows for Inflammation Research

  2026-08-15

  Use Indomethacin to separate cyclooxygenase-driven inflammation from PPARγ, lipid, and membrane effects in controlled cell assays. This workflow also shows how the FXR–KLF11 findings from recent kidney-injury research can sharpen pathway controls without treating Indomethacin as an FXR agonist.

• Ciclesonide: Prodrug Mechanism and Research Use

  2026-08-15

  Ciclesonide is a lung-activated glucocorticoid prodrug whose metabolite, desisobutyryl-ciclesonide, has substantially greater reported potency. Its activation profile supports asthma treatment research, airway inflammation assays, and allergic rhinitis treatment studies.

452 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page